Lunai Bioworks Inc Com (LNAI:OTC) closed at $0.165 on October 29, 2026, unchanged on the day. The stock trades 98.8% below its 52-week high of $13.28 and 16.9% above its 52-week low of $0.141. Over the past year, it lost 81.1%. Lunai Bioworks Inc Com is part of the Health Care sector.
In 252 trading sessions since October 30, 2025, LNAI closed higher on 84 days (33%). Its best day was November 24, 2025 (+719.35%) and its worst was October 23, 2026 (-37.23%). The stock moved 10% or more in a single session 51 times. It opened at least 5% above the previous day's high 10 times.
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023.
Find more stocks like LNAI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.